Vigil Neuroscience Investor Relations Material

Vigil Neuroscience, Inc. is a clinical-stage biotechnology company focusing on developing treatments for both rare and common neurodegenerative diseases. The company aims to enhance the function of microglia, which are critical immune cells in the brain, to combat these diseases. Vigil Neuroscience's approach involves using precision medicine to develop targeted drug candidates, particularly focusing on the triggering receptor expressed on myeloid cells 2 (TREM2). Their drug development programs are centered on activating TREM2 to address conditions associated with microglial dysfunction, such as Alzheimer's disease. The company is headquartered in Watertown, Massachusetts, and its shares are listed on the NASDAQ.